HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer.

Dr Axel Hoos

Non-Executive Director

Dr. Axel Hoos is Senior Vice President and Therapeutic Area Head, Oncology R&D at GlaxoSmithKline Pharmaceuticals (GSK).  As leader of the Oncology TA he oversees both its discovery and development functions and builds the Oncology portfolio of GSK across several modalities including antibodies, small molecules, bispecific molecules and cell & gene therapies. The TA’s scientific focus is on Immuno-Oncology, Epigenetics and Cell Therapy.

Dr. Hoos also serves on the Scientific Advisory Board of the HIV Cure Center, a co-venture of GSK and the University of North Carolina at Chapel Hill.

Dr. Hoos further serves as Executive Chairman of the Board of Trustees of the Sabin Vaccine Institute (SVI), a Global Health organization, Co-Chairman of the Cancer Immunotherapy Consortium (CIC) and Scientific Advisory Board Member of the Cancer Research Institute (CRI). He further is a Scientific Advisory Group member at the Parker Institute for Cancer Immunotherapy (PICI), and Industry Co-Chair of the Partnership for Acceleration Cancer Therapies (PACT) of the U.S. Cancer Moonshot. His efforts in Medicines Development and Global Health focus on novel and transformational therapies for life-threatening diseases, scientific and procedural innovation, and broad collaboration across multiple constituents to solve complex health problems. Through his leadership a new paradigm for the development of cancer immunotherapies has been defined, which helped launch the field of Immuno-Oncology. 

Previously, Dr. Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS) where he developed Yervoy (Ipilimumab), the first life-extending therapy in Immuno-Oncology. Before BMS, Dr. Hoos was Senior Director of Clinical Development at Agenus Bio (previously Antigenics), a biotech company. 

Dr. Hoos holds an MD from Ruprecht-Karls-University and a PhD in molecular oncology from the German Cancer Research Center (DKFZ) both in Heidelberg, Germany. He trained in surgery at the Technical University in Munich, Germany and further in surgery, molecular pathology and tumor immunology at Memorial Sloan-Kettering Cancer Center in New York City. He is an alumnus of the Program for Leadership Development at Harvard Business School. 

 

 
 
 

© Imugene 2018. All rights reserved. ABN 99 009 179 551